Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocon Limited ( (IN:BIOCON) ) has shared an announcement.
Biocon Limited announced that the U.S. FDA has classified its Biocon Biologics’ Drug Substance Facility in Bengaluru as Voluntary Action Indicated (VAI) following an inspection. This classification pertains to the production of Human Recombinant Insulin and Biosimilar Pegfilgrastim Drug Substance for the U.S. market, reinforcing Biocon’s commitment to maintaining high standards of quality and compliance.
More about Biocon Limited
Biocon Limited is a prominent player in the biotechnology industry, primarily focusing on the development and production of biopharmaceuticals. The company specializes in manufacturing biosimilars, generic biologics, and novel biologics, with a significant market focus on providing affordable healthcare solutions globally.
Average Trading Volume: 122,237
Technical Sentiment Signal: Strong Buy
Current Market Cap: 524.6B INR
Learn more about BIOCON stock on TipRanks’ Stock Analysis page.